44.200.137.63
dgid:
enl:
npi:0
Ophthalmology
Trending Topics

Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

Posted on

Allergan plc, a leading global pharmaceutical company, and Editas Medicine, Inc, a leading genome editing company, today announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN-151587 (EDIT-101) at Oregon Health & Science University (OHSU) Casey Eye Institute, a world-recognized academic eye center.

AGN-151587 (EDIT-101) is an experimental medicine delivered via sub-retinal injection under development for the treatment of Leber congenital amaurosis 10 (LCA10), an inherited form of blindness caused by mutations in the centrosomal protein 290 (CEP290) gene. The BRILLIANCE clinical trial is a Phase 1/2 study to evaluate AGN-151587 for the treatment of patients diagnosed with LCA10 and is the world’s first human study of an in vivo, or inside the body, CRISPR genome editing medicine. The trial will assess the safety, tolerability, and efficacy of AGN-151587 in approximately 18 patients with LCA10.

Read the full press release here.

Source: Editas Medicine, Inc.; Allergan plc
-Advertisement-
Related Articles
Implantable Miniature Telescope for Advanced AMD
Oct 14, 2020
Treating AMD Patients with New Technology
Oct 14, 2020
What is DME?
Oct 14, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-